A continued saga of Boc5, the first non-peptidic glucagon-like peptide-1 receptor agonist with in vivo activities

Authors: Min He, Ni Guan, Wei-wei Gao, Qing Liu, Xiao-yan Wu, Da-wei Ma, Da-fang Zhong, Guang-bo Ge, Chuan Li, Xiao-yan Chen, Ling Yang, Jia-yu Liao, Ming-wei Wang
DOI: 10.1038/aps.2011.169


Glucagon-like peptide-1 (GLP-1)-based therapy presents a promising option for treating type 2 diabetes. However, there are several limitations relative to the peptidic GLP-1 mimetics currently on the market or under development. This concern has led to a continued interest in the search for non-peptidic agonists for GLP-1 receptor (GLP-1R). Here, we briefly review the discovery, characterization and current status of a novel class of cyclobutane-derivative-based non-peptidic agonists for GLP-1R, including Boc5 and its newly discovered analogue WB4–24. Although the oral bioavailability of such compounds still poses great challenges, the progress made so far encourages us to identify a truly 'druggable' small molecule agonist for GLP-1R.

Article Options

Download Citation

Cited times in Scopus